International Stem Cell Corp
internationalstemcell.comWhat Do They Do?
Sells human cells and cell-culture supplies to research customers, skin-care products to retail and professional buyers, and develops stem-cell candidates for neurological disorders.
10-K for FY2025, filed Mar 30, 2026Biomedical Market – Primary Human Cell Research ProductsView ↗
LSC phased out its retail product line in 2019, with the exception of select cleanser products that were offered to both professional and…View ↗
We believe that the most promising potential clinical applications of our technology are Parkinson’s disease (“PD”), traumatic brain injury…View ↗
How Do They Make Money?
Research customers buy human cells and cell-culture supplies, generally paying 30 days after shipment; online skin-care orders are paid at purchase.
10-K for FY2025, filed Mar 30, 2026
-
10-K for FY2025, filed Mar 30, 2026
FY2025 revenue by reportable segment ↗
$9.1M
-
10-K for FY2025, filed Mar 30, 2026
$9.1M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Biomedical Market
Sold outright
10-K for FY2025, filed Mar 30, 2026 |
93%
FY2022: 87%
|
Biomedical Market, FY2025
$8.5M Sources
|
Sold outright |
|
Anti-aging Market
Sold outright
|
6.6%
FY2022: 13%
|
Anti-aging Market, FY2025
$598K Sources
|
Sold outright |
Who Are Their Customers?
Research products are sold through the company’s sales force, OEM partners, and distributors in Europe and Asia. Skin care is sold through its website, Amazon and other online partners, plus some professional accounts.
10-K for FY2025, filed Mar 30, 2026Biomedical Market – Primary Human Cell Research ProductsView ↗
LSC’s products are regulated as cosmetics. LSC’s products are sold domestically through a branded website, Amazon, and ecommerce partners.View ↗
LSC phased out its retail product line in 2019, with the exception of select cleanser products that were offered to both professional and…View ↗
10-K for FY2025, filed Mar 30, 2026
For the years ended December 31, 2025 and 2024, one customer accounted for approximately 54% and 53%, respectively, of consolidated product…View ↗
Do Revenues Turn Into Profits?
No. It lost $418K in FY2025.
10-K for FY2025, filed Mar 30, 2026
−$267KView ↗
10-K for FY2025, filed Mar 30, 2026
−$418KView ↗
10-K for FY2025, filed Mar 30, 2026
−$35KView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$71KView ↗
- ▼ Now a loss
- vs $129K in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 13, 2026
Open tableView ↗
-
Sep 1, 2026
Sold Lifeline Cell Technology to American Type Culture Collection
The adjusted purchase price was $25,250,000, subject to a post-closing working capital true-up.
Sources
8-K, filed Sep 8, 2026
On September 1, 2026, International Stem Cell Corporation (the “Company”) completed the sale of 100% of the membership interests of its…View ↗
Growing. Revenue grew 27% in 4 years, from $7.2M in FY2021 to $9.1M in FY2025, about 6% a year.
Who Do They Compete With?
Competes with BioTime, SanBio, BlueRock Therapeutics, ReNeuron, Obagi, ZO Skin Health, Skinceuticals, SkinMedica, Murad, Lonza, EMD Millipore, Life Technologies, StemCell Technologies, Zen-bio, PromoCell, and Specialty Media
10-K for FY2025, filed Mar 30, 2026Some of our primary competitors in the development of stem cell therapies are BioTime, SanBio, BlueRock Therapeutics, and ReNeuron. Our…View ↗
Loading...
